Prato

• Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R … Pending
  2024-519818-31-01 5 Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresec
• Prevention of Ribociclib-related hepatotoxicity in breast cancer patients: a phase II, multicentre, open label, single arm trial of Silimari … Pending
  2025-521651-22-00 4 hormone receptor positive, HER2-negative breast cancer
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• A clinical study to assess the efficacy of adjuvant immunotherapy with cemiplimab in patients with surgically removed non-small cell lung ca … Recruiting
  2024-519901-36-00 5 2025-12-17 Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC
• Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer. A randomized phase III trial. LEPRE Trial Recruiting
  2024-516874-31-00 5 2024-12-10 Patients with a low-grade serous epithelial carcinoma of the ovary (LG
• A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Teno … Recruiting
  2023-510422-32-00 5 2024-09-10 Tenosynovial Giant Cell Tumour
• Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s … Recruiting
  2022-501606-35-01 11 2024-02-21 Platinum-sensitive epithelial ovarian, fallopian tube, or primary peri
• ENGIC 02 - PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanc … Recruiting
  2023-505486-92-00 4 2024-02-09 Small bowel adenocarcinoma
• A clinical study of ABSK021 in Patients with Tenosynovial Giant Cell Tumor to determine whether the study drug is safe and how well the ant … Recruiting
  2023-503245-58-00 5 2023-10-04 Tenosynovial Giant Cell Tumor
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting
  2025-522873-12-00 5 2026-02-24 ER+, HER2- Advanced Breast Cancer
• Phase II study of lurbinectedin and irinotecan in adult and young adult patients with advanced desmoplastic small round cell tumor (DSRCT) Recruiting
  2024-519261-21-00 4 2025-11-21 Desmoplastic small round cell tumor
• Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced … Recruiting
  2024-519871-24-00 10 2025-11-11 Breast cancer
• CATALINA-2: A Phase 2 Study of TORL-1-23 in Advanced Ovarian Cancer Recruiting
  2024-517190-24-00 4 2025-09-16 Peritoneal Cancer
• ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting
  2024-514030-20-00 4 2025-08-29 colorectal cancer
• Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste … Recruiting
  2023-508507-20-00 5 2025-04-03 Locally advanced or metastatic conventional chondrosarcoma with an IDH
• Gemcitabine plus nab-PAclitaxel as switch maiNTEnance versus cONtinuation of modified FOLFIRINOX as first-line chemotherapy in patients with … Recruiting
  2024-515214-41-00 5 2025-03-27 advanced pancreatic cancer
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI … Recruiting
  2024-517863-22-00 5 2024-12-01 Study population consists in patients with a diagnosis of mCRC who hav
• PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRES … Recruiting
  2023-506632-32-00 5 2024-10-28 Metastatic colorectal cancer
• Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer … Recruiting
  2023-505616-38-00 4 2024-09-04 Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un … Recruiting
  2023-508613-17-00 5 2024-05-29 Neoplasms, Head and Neck
• Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patie … Recruiting
  2023-506662-31-00 4 2024-02-28 Gastric or gastroesophageal cancer
• IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-contr … Recruiting
  2023-506620-87-00 11 2024-01-25 Advanced Breast Cancer in older patients

Showing 1–24 of 56 trials